Cytokinetics has reported detailed Phase 3 results showing that aficamten significantly improved both symptoms and exercise capacity in adults with symptomatic non-obstructive hypertrophic cardiomyopathy, delivering the first successful pivotal trial in a disease setting where no therapy is currently approved to directly address the underlying cardiac dysfunction. The ACACIA-HCM results were presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine, while Cytokinetics plans to submit a supplemental New Drug Application to the United States Food and Drug Administration during the fourth quarter of 2026.
The full dataset substantially expands on positive topline findings disclosed in May and puts aficamten within reach of potentially becoming the first cardiac myosin inhibitor approved across both obstructive and non-obstructive forms of symptomatic hypertrophic cardiomyopathy. That possibility carries additional significance because Bristol Myers Squibb’s competing cardiac myosin inhibitor mavacamten previously failed to meet its dual primary endpoints in the Phase 3 ODYSSEY-HCM study of non-obstructive disease.
ACACIA-HCM succeeds on both symptoms and exercise capacity in a difficult HCM population
ACACIA-HCM was a randomized, double-blind, placebo-controlled Phase 3 study involving 517 participants with symptomatic non-obstructive hypertrophic cardiomyopathy. Patients were randomized equally to aficamten or placebo, with treatment titrated according to echocardiographic monitoring and efficacy assessed across two prespecified primary endpoints after 36 weeks.
The first endpoint measured changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, which captures symptoms and physical limitations from the patient perspective. Patients receiving aficamten improved by an adjusted mean 11.4 points compared with 8.4 points for placebo, producing a statistically significant three-point treatment difference.
The second primary endpoint measured peak oxygen uptake during exercise testing, an objective assessment of functional capacity. Peak oxygen uptake increased by 0.64 milliliters per kilogram per minute with aficamten compared with a decline of 0.03 in the placebo group, producing a treatment difference of 0.67 milliliters per kilogram per minute. The result was statistically significant with a P value of 0.003.
Importantly, treatment effects on both primary endpoints remained consistent across prespecified subgroups, including age, sex, genotype, atrial fibrillation status, baseline left ventricular ejection fraction and use of background beta blockers. That consistency may strengthen the regulatory argument that the observed benefits are not confined to a narrow subgroup within the broader symptomatic population.
The study also produced positive findings across several ranked secondary measures. Approximately 41.9% of aficamten-treated patients improved by at least one New York Heart Association functional class compared with 27.8% receiving placebo. Aficamten also produced significant improvements in combined cardiopulmonary exercise measures and substantially lowered NT-proBNP, a biomarker associated with cardiac wall stress.
Aficamten succeeds where an earlier cardiac myosin inhibitor trial fell short
The results are particularly notable because non-obstructive hypertrophic cardiomyopathy has been a difficult target for drug development. Unlike obstructive disease, where excessive cardiac muscle contraction produces a measurable blockage of blood exiting the heart, non-obstructive hypertrophic cardiomyopathy lacks significant outflow obstruction while still producing symptoms including breathlessness, fatigue, chest discomfort and reduced exercise tolerance.
Patients currently lack an approved therapy specifically targeting the underlying disease mechanism in symptomatic non-obstructive hypertrophic cardiomyopathy. That unmet need became even more visible after Bristol Myers Squibb reported in 2025 that its Phase 3 ODYSSEY-HCM study of mavacamten failed to demonstrate statistically significant improvements in either peak oxygen uptake or the Kansas City Cardiomyopathy Questionnaire endpoint.
The contrast does not establish that aficamten is clinically superior to mavacamten because the two drugs were evaluated in separate trials with different designs and populations. However, the successful ACACIA-HCM outcome gives Cytokinetics an opportunity that the broader cardiac myosin inhibitor class had previously failed to secure.
Cytokinetics has indicated that the totality of ACACIA-HCM results supports its plan to seek expanded regulatory approval. If regulators agree, aficamten could become the first therapy in its class spanning symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy, potentially widening the commercial opportunity considerably beyond its existing indication.
Safety findings will receive close attention as FDA reviews the expanded aficamten opportunity
The efficacy results were accompanied by safety findings that will remain important during regulatory review. Serious adverse events occurred in 20.2% of patients receiving aficamten compared with 14.7% receiving placebo, while non-fatal adverse events leading to treatment discontinuation occurred in 7% and 1.9%, respectively.
Reduced left ventricular ejection fraction below 50% occurred in 27 patients receiving aficamten, representing 10.5% of the treatment group, compared with two patients receiving placebo. Two aficamten-treated participants experienced serious heart failure events associated with an ejection fraction below 50%, while additional heart failure events were reported without that reduction in ejection fraction. Cytokinetics reported that the heart failure events occurred during dose titration or before week 12 and were generally responsive to short courses of diuretic treatment.
Those findings underscore the importance of careful dose management and cardiac monitoring if aficamten eventually enters routine use in non-obstructive hypertrophic cardiomyopathy. They also give regulators a more complex benefit-risk calculation than the positive efficacy endpoints alone might suggest.
At the same time, 53% of aficamten-treated patients achieved a clinical response across at least three of five assessed disease domains compared with 13% receiving placebo. The analysis incorporated exercise capacity, cardiac structure, biomarkers, diastolic function and symptom burden, suggesting that the treatment effect extended across several aspects of the disease rather than being confined to a single measurement.
Myqorzo commercial launch gives Cytokinetics an existing platform for a broader HCM indication
Aficamten is already marketed as Myqorzo for adults with symptomatic obstructive hypertrophic cardiomyopathy in the United States and has also secured approvals in China, the European Union and the United Kingdom. Cytokinetics generated $25.3 million in second-quarter 2026 Myqorzo net product revenue, including $23 million from the United States and initial German sales.
That existing commercial infrastructure could become strategically important if the non-obstructive indication is approved. Rather than building a new launch organization from scratch, Cytokinetics would be expanding an established cardiovascular product into another segment of the same disease spectrum, potentially allowing existing specialist relationships and reimbursement infrastructure to support uptake.
The company also enters the regulatory process with substantial financial resources. Cytokinetics reported approximately $1.7 billion in cash, cash equivalents and investments at June 30 after raising roughly $760 million through a public offering during the second quarter. The balance sheet provides considerable flexibility to finance Myqorzo commercialization while supporting additional cardiovascular development programs.
The commercial opportunity will depend on the final label, monitoring requirements, reimbursement and the size of the diagnosed symptomatic population suitable for treatment. Even so, successfully extending aficamten into non-obstructive disease would materially strengthen Myqorzo’s potential to become a broader hypertrophic cardiomyopathy franchise rather than a therapy restricted to obstructive disease.
Cytokinetics shares fall despite positive trial as investors weigh efficacy against expectations and safety
The market response has been surprisingly negative. Cytokinetics shares were down about 5% near $74 during morning trading despite the successful Phase 3 results, after closing at $77.90 on August 27. The stock remains well above its 52-week low of $35.22 but below its recent high of $88.31.
The decline suggests that investors are examining the detailed dataset more critically than the headline trial success might imply. Positive topline results had already been disclosed in May, meaning much of the efficacy success was known before the European Society of Cardiology presentation. The detailed safety findings, the magnitude of the placebo-adjusted symptom improvement and elevated expectations ahead of the full readout may therefore be contributing to the selloff.
That reaction does not diminish the regulatory importance of ACACIA-HCM. Cytokinetics now has the first successful Phase 3 program in symptomatic non-obstructive hypertrophic cardiomyopathy and plans to put those data before the United States Food and Drug Administration within months. Whether the commercial opportunity ultimately matches investor expectations will depend on regulatory interpretation, prescribing restrictions and real-world adoption.
The next major milestone is therefore straightforward. Cytokinetics needs to convert the statistically positive ACACIA-HCM dataset into an expanded Myqorzo label while demonstrating that the efficacy benefit is compelling enough to justify the monitoring and safety considerations associated with cardiac myosin inhibition. A successful fourth-quarter submission could move that question from clinical development into regulatory review before the end of 2026
